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Abstract
Tumour necrosis factor (TNF) is considered to be a major factor
in chronic synovial inflammation and is an inducer of mitogen-
activated protein kinase (MAPK) signalling. In the present study
we investigated the ability of TNF to activate MAPKs in the
synovial membrane in vivo. We studied human TNF transgenic
mice – an in vivo model of TNF-induced arthritis – to examine
phosphorylation of extracellular signal-regulated kinase (ERK),
c-Jun amino terminal kinase (JNK) and p38MAPKα  in the
inflamed joints by means of immunoblot and
immunohistochemistry. In addition, the effects of systemic
blockade of TNF, IL-1 and receptor activator of nuclear factor-
κ B (RANK) ligand on the activation of MAPKs were assessed.
In vivo, overexpression of TNF induced activation of p38MAPKα
and ERK in the synovial membrane, whereas activation of JNK
was less pronounced and rarely observed on
immunohistochemical analysis. Activated p38MAPKα  was
predominantly found in synovial macrophages, whereas ERK
activation was present in both synovial macrophages and
fibroblasts. T and B lymphocytes did not exhibit major activation
of any of the three MAPKs. Systemic blockade of TNF reduced
activation of p38MAPKα  and ERK, whereas inhibition of IL-1
only affected p38MAPKα  and blockade of RANK ligand did not
result in any decrease in MAPK activation in the synovial
membrane. These data indicate that TNF preferentially activates
p38MAPKα  and ERK in synovial membrane exposed to TNF.
This not only suggests that targeted inhibition of p38MAPKα
and ERK is a feasible strategy for blocking TNF-mediated
effects on joints, but it also shows that even currently available
methods to block TNF effectively reduce activation of these two
MAPKs.
Introduction
Chronic inflammation of the synovial membrane (synovitis) is a
hallmark of rheumatoid arthritis (RA). This process is fueled by
proinflammatory cytokines, which not only induce but also
maintain synovitis and therefore play an important role in pro-
gressive joint destruction [1,2]. Several cytokines are currently
considered to be key molecules in joint inflammation, but the
evidence that tumour necrosis factor (TNF) is crucial to devel-
opment of chronic destructive arthritis is most compelling. This
is primarily supported by the clinical efficacy of TNF blocking
agents in the treatment of RA but also by the fact that overex-
pression of TNF is sufficient to cause inflammatory arthritis in
mice [3-7]. In addition, expression of TNF has been detected
in the synovial membrane of RA patients, and cultivated cells
from the synovial tissue produce increased amounts of TNF [8-
10].
The effects of TNF-α  are mediated via a complex network of
signalling pathways. Apart from activation of nuclear factor-κ B,
many signals are transduced through mitogen-activated pro-
tein kinases (MAPKs), which include extracellular signal-regu-
lated kinase (ERK), c-Jun amino-terminal kinases (JNK) and
p38MAPKα  [11]. These molecules mediate activation of many
key transcription factors, such as the activator protein-1 com-
plex, which then facilitates induction and transcription of the
relevant proinflammatory genes, such as cytokines, chemok-
ines and matrix metalloproteinases [12]. Indeed, these struc-
tures are considered to be promising therapeutic targets, and
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several small molecule based inhibitors are currently being
tested for their antiarthritogenic potential [13-16].
It is currently unclear whether TNF equally activates all three
MAPK families in arthritis or has a certain predilection toward
activating one of the families in the synovial tissue in vivo.
Despite the potential of TNF to activate all three MAPKs, the
pathways that are of relevance to chronic destructive arthritis
remain to be elucidated. However, if we are to design thera-
peutic tools that can effectively block TNF-mediated inflamma-
tory responses, then we must define the major signalling
targets of TNF in inflammatory joint disease in vivo. Interest-
ingly, all three MAPK families – p38MAPKα , ERK and JNK –
are activated in RA synovial membrane, and TNF-α  has the
potential to signal through all of them [17,18]. Therefore, each
of these different MAPKs is a potential therapeutic target.
In the present study we investigated the effect of in vivo over-
expression of TNF on MAPK signalling in synovial tissue. Mice
transgenic for human TNF (hTNFtg mice), which develop a
chronic inflammatory joint disease, were assessed for immu-
nohistochemical evidence of activation of the three MAPK
families (ERK, JNK and p38MAPKα ). Moreover, we defined
the cell types in the synovial membrane that exhibit MAPK acti-




Heterozygous Tg197 human TNF-α  transgenic (hTNFtg) mice
(strain C57/Bl6), which develop a chronic inflammatory and
destructive polyarthritis within 4–6 weeks after birth, were
described previously [7]. We investigated five groups of
hTNFtg mice aged 10 weeks, of which one group was left
untreated. Of the other four groups one was treated with anti-
TNF (infliximab; Centocor, Leiden, The Netherlands) at a dose
of 10 mg/kg three times weekly via intraperitoneal injection;
one group received a recombinant IL-1 receptor antagonist
(anakinra; Amgen, Thousand Oaks, CA, USA) given by contin-
uous infusion at a dose of 5 mg/kg per hour using a subcuta-
neously implanted minipump (Alzet; Durect Corp., Cupertino,
CA, USA) as previously described [19]; group 4 received
osteoprotegerin (Fc-osteoprotegerin fusion protein; Amgen),
which is a blocker of the interaction between receptor activa-
tor of nuclear factor-κ B (RANK) ligand and RANK, at a dose of
10 mg/kg three times weekly by intraperitoneal injection [20];
and group 5 received phospate-buffered saline (PBS) buffer
only. Treatment was started at the stage of early arthritis (week
6) and lasted for 4 weeks. Mice were killed by cervical dislo-
cation at age 10 weeks, blood was drawn by heart puncture,
and the hind paws were dislocated for histological and immu-
nohistochemical evaluation. All animal procedures were
approved by the local ethics committee.
Preparation and histological evaluation of decalcified 
specimen
Left and right hind paws were fixed in 4.5% buffered formalin
overnight and then decalcified in 14% EDTA (Sigma, St.
Louis, MO, USA; pH adjusted to 7.2 by addition of ammonium
hydroxide) at 4°C until the bones were pliable. Serial paraffin
sections (2 µm) of the right hind paw were used for the immu-
nohistochemical analyses.
Immunohistochemistry of phosphorylated MAPKs
For immunohistochemical detection of the phosphorylated
forms of ERK, p38MAPKα  and JNK, ethanol dehydrated tissue
sections were treated with 3% hydrogen peroxide in methanol
followed by digestion with proteinase K (25 mg proteinase K
in 50 ml PBS) for 5 min at 37°C and blocking with PBS buffer
containing 20% rabbit serum for 1 hour. Then, sections were
incubated with monoclonal antibodies to the phosphorylated
isoforms of ERK-1 and ERK-2 (clone E-4, dilution 1:20),
p38MAPKα  (clone D-8, dilution 1:5) and JNK (clone G-7, dilu-
tion 1:200; all from Santa Cruz Biotechnology, Santa Cruz,
CA, USA) at room temperature for 1 hour and for 30 min with
biotinylated goat anti-mouse immunoglobulin (Santa Cruz bio-
technology). Antibody binding was detected using an ABC
complex (for p38MAPKα  and ERK: VECTASTAIN@ABC rea-
gent, Vector, Burlingame, CA, USA; for JNK: StreptABCom-
plex/HRP, Dako, Glostrup, Denmark) and 3,3-
diaminobenzidine (DAB; Sigma) as chromogen, resulting in
brown staining of antigen-expressing cells.
Cell-specific double labelling experiments
Characterization of cells expressing ERK, p38MAPKα  and
JNK was performed by double staining using cell-type specific
antibodies. After applying the protocol as described above,
the slides were incubated with rat anti-mouse monoclonal anti-
bodies against macrophages (F4/80; Serotec Inc., Raleigh,
NC, USA; diluted 1:100), T cells (anti-CD3; Novocastra, New-
castle, UK; diluted 1:200) and fibroblasts (Biogenesis, Dorset,
UK; diluted 1:40). Thereafter, the sections were incubated by
an alkaline phosphatase conjugated rabbit anti-rat immu-
noglobulin (Dako) and the reaction was visualized using a rat
alkaline phosphatase–antialkaline phosphatase complex
(Dako), nitroblue tetrazolium (0.25 µg/ml) and 5-bromo-4-
chloro-3-indolyl phosphate (0.125 µg/ml). In case of staining
for B cells (rat monoclonal antibody against CD45R/B220;
BD Biosciences Pharmingen, San Jose, CA, USA; diluted
1:300) the cell-specific antibody was applied first and
detected by ABC/DAB with subsequent staining of ERK,
p38MAPKα  and JNK, and detection with a mouse-specific
alkaline phosphatase–antialkaline phosphatase complex sys-
tem (Dako). Expression of ERK, p38MAPKα  and JNK was
quantitatively assessed by counting both total numbers of syn-
ovial cells and the numbers of positively stained cells in each
immunohistochemical staining using a magnification of 200×
or by counting positively stained cells per high power field
(magnification 400×).Available online http://arthritis-research.com/content/7/5/R1140
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Immunoblotting
Hind paws from three wild-type and three hTNFtg mice aged
10 weeks were snap frozen in liqid nitrogen and mechanically
homogenized at 4°C in buffer containing 20 mmol/l HEPES,
0.4 mol/l NaCl, 1.5 mmol/l MgCl2, 1 mmol/l DTT, 1 mmol/l
EDTA, 0.1 mmol/l EGTA and 20% glycerol, as well as pro-
tease and phosphatase inhibitors (protease and phosphatase
inhibitor cocktail, cataolgue numbers P8340 and P2850;
Sigma) using an Ultra-Turrax T50 homogenizer (Rose Scien-
tific Ltd., Edmonton, Al, Canada). Tissue extracts were then
separated from debris and fat by centrifuging at 13,000 rpm
for 15 min. Protein content was measured by Bradford assay
and 200 µg tissue protein was subjected to electrophoresis
on a 10% SDS polyacrylamide gel followed by transfer onto
nitrocellulose membranes. After blocking, the membranes
were incubated by antibodies against the phosphorylated as
well as total p38MAPKα , ERK and JNK (all antibodies from
Cell Signaling, Beverly, MA, USA).
Statistical analysis
Data are expressed as mean ± standard error of the mean.
Expression of ERK, p38MAPKα  and JNK in the different ther-
apy groups and cell types was compared by means of
Kruskal–Wallis test and Dunn's multiple comparison test.
Results
Systemic overexpression of TNF leads to activation of 
p38MAPKα  and ERK pathways in the synovial membrane
To gain an overview of MAPK expression in TNF-mediated
arthritis, paw extracts from wild-type and arthritic hTNFtg mice
were analyzed for the activated phosphorylated forms of
p38MAPKα , ERK and JNK. Paws of hTNFtg mice exhibited
marked activation of both p38MAPKα  and ERK (Fig. 1a,c)
compared with wild-type mice. In contrast, only weakly
increased activation of JNK was found (Fig. 1e). Total amounts
of p38MAPKα , ERK and JNK were not different among wild-
type controls and arthritic hTNFtg mice (Fig. 1b,d,f). To inves-
tigate more closely the activation of MAPK by TNF in vivo, we
histologically assessed joints of hTNFtg mice and wild-type
mice for phosphorylated forms of p38MAPKα , ERK and JNK.
Synovial inflammatory tissue of hTNFtg mice exhibited wide-
spread activation of p38MAPKα  and ERK. Expression of
phosphorylated forms of both p38MAPKα  and ERK was abun-
dant at sites of destructive synovial pannus but also in the syn-
ovial lining layer (Fig. 2a,b,d,e). In contrast, activation of JNK
was far less frequent and confined to a few cells within syno-
vial pannus and the synovial lining (Fig. 2c,f). Compared with
hTNFtg mice, synovial tissue of wild-type mice exhibited little
activation of all three MAPKs (Fig. 2g–i), at most confined to
scattered cells in the synovial lining.
We performed a quantitative analysis of MAPK activation, and
found p38MAPKα  to be activated in 24 ± 4% of synovial cells
of hTNFtg mice whereas it was only activated in 5 ± 1% in the
synovium of wild-type mice (Fig. 2j). Similarly, activation of
ERK was significantly higher in synovial tissue of hTNFtg (23
± 4%) than wild-type mice (7 ± 2%; Fig. 2k). Activation of JNK
was considerably less frequent than each of the two other
MAPKs, accounting for 8 ± 2% of cells in the synovial mem-
brane of hTNFtg mice and being virtually absent in wild-type
mice (Fig. 2l).
Macrophages and fibroblasts dominate MAPK activation 
in the synovial membrane
To investigate the cellular expression of the three MAPKs in
more detail, we performed immunohistochemical double stain-
ing with cell type specific antibodies against macrophages, T
Figure 1
TNF leads to activation of MAPK in arthritic joints of hTNFtg mice TNF leads to activation of MAPK in arthritic joints of hTNFtg mice. 
Pooled protein extracts from three normal wild-type mice (left lanes) as 
well as three arthritic human tumour necrosis factor transgenic 
(hTNFtg) mice (right lanes) aged 10 weeks were analyzed for the phos-
phorylated forms of (a) p38 mitogen-activated protein kinase (MAPK)α , 
(c) extracellular signal regulated kinase (ERK), and (e) c-Jun amino-ter-
minal kinase (JNK) by immunoblotting. In addition, total (b) p38MAPKα , 
(d) ERK and (f) JNK, as well as (g) actin, were analyzed.Arthritis Research & Therapy    Vol 7 No 5    Görtz et al.
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lymphocytes, B lymphocytes and fibroblasts. Activation of
p38MAPKα  was most frequent in macrophages (44 ± 5%;
Fig. 3a,i). In contrast, a significantly (P < 0.01) lower propor-
tion of T lymphocytes (7 ± 3%), B lymphocytes (9 ± 4%) and
fibroblasts (11 ± 1%) exhibited activation of p38MAPKα  (Fig.
3c,e,g,i). Similarly, ERK activation was found predominantly in
macrophages (43 ± 3%; Fig. 3b,j); however, activation in syn-
ovial fibroblasts was also frequently observed (26 ± 4%; Fig.
3d,j). Activation of ERK was significantly (P < 0.01) less fre-
quent among T lymphocytes (13 ± 6%) and B lymphocytes (6
± 2%; Fig. 3f,h,j). As described above, activation of JNK was
generally weak. When present, it was found predominately in
macrophages, of which 14 ± 2% were positive. Activation of
JNK in fibroblasts (6 ± 3%), T lymphocytes (9 ± 5%) and B
lymphocytes (3 ± 2%) was generally very low (Fig. 3k).
TNF but not IL-1 and RANK ligand blockade reduces both 
p38MAPKα  and ERK activation in the inflamed synovial 
membrane
We next addressed whether cytokine blockade affected
increased activation p38MAPKα , ERK and JNK in the inflamed
synovial tissue. We compared the activation of these proteins
in synovial tissue of hTNFtg mice after systemic inhibition of
TNF, IL-1 and RANK ligand. Activation of p38MAPKα  was sig-
nificantly (P  < 0.05) inhibited by TNF and IL-1 blockade,
reducing the fraction of synovial cells exhibiting p38MAPKα
activation by 53% and 55%, respectively (Fig. 4a). In contrast,
blockade of RANK ligand by osteoprotegerin had no effect on
activation of p38MAPKα  in synovial tissue. Activation of ERK
was significantly affected by TNF blockade only, exhibiting a
significant reduction by 48% compared with untreated
Figure 2
Expression of MAPK in synovial lining and pannus cells of hTNFtg mice and wild-type mice Expression of MAPK in synovial lining and pannus cells of hTNFtg mice and wild-type mice. The phosphorylated forms of (a,d,g) p38 mitogen-acti-
vated protein kinase (MAPK)α , (b,e,h) extracellular signal-regulated kinase (ERK), and (c,f,i) c-Jun amino-terminal kinase (JNK) were stained in both 
the synovial pannus (panels a–c) and the synovial lining layer (panels d–f) of human tumour necrosis factor transgenic (hTNFtg) mice as well as in 
wild-type mice (panels g–i). p38MAPKα  and ERK were abundantly activated in hTNFtg mice but not in wild-type mice (brown staining, black 
arrows). In contrast, JNK was activated far less frequently and only in a few cells within synovial pannus as well as the synovial lining in hTNFtg mice. 
In wild-type mice, activation of MAPKs was generally low. Original magnification 1000×. Quantitative analysis showed a significantly higher expres-
sion of (j) p38MAPKα  and (k) ERK in hTNFtg mice compared with wild-type mice, but no significant difference in (l) JNK activation. Data are 
expressed as mean ± standard error of the mean. *P < 0.05. WT, wild-type.Available online http://arthritis-research.com/content/7/5/R1140
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hTNFtg mice (Fig. 4b). In contrast, both IL-1 and RANK ligand
blockade had no effect on ERK activation in the synovial tis-
sue. JNK activation, which was relatively weak compared with
the two other signalling molecules, was not altered by any of
the three cytokine blockers (Fig. 4c).
Discussion
In the present study we used hTNFtg mice as an in vivo model
to define the effects of TNF on MAPK activation the synovial
membrane. Cytokine induced signalling through MAPK is con-
sidered to be an important mechanism of joint inflammation
and represents an interesting option for future antirheumatic
therapies [16,17]. We found that TNF predominantly activates
p38MAPKα  and ERK in the synovial membrane, whereas JNK
activation is less common. Furthermore, we were able to dem-
onstrate that macrophages and synovial fibroblasts are the
major targets for TNF-induced MAPK induction. Activation of
p38MAPKα  is clearly dominant in synovial macrophages,
whereas activation of ERK is additionally found in synovial
fibroblasts. In contrast, TNF-induced activation of MAPK
appears not to be critical in lymphocytes. We also showed that
cytokine blockade, especially blockade of TNF, effectively
interferes with MAPK activation.
TNF is a pluripotent cytokine, which has the potential to induce
highly divergent cellular effects. Dependent on the signalling
pathway used, TNF can promote cell survival but also pro-
grammed cell death, and it is involved in different processes
such as inflammation and host defence [11,21,22]. More
detailed information on the signalling molecules employed by
TNF in chronic inflammation will extend our understanding of
how TNF promotes synovitis and may indicate which targeted
Figure 3
Cell-specific activation of p38MAPKα , ERK and JNK in the inflamed synovial membrane Cell-specific activation of p38MAPKα , ERK and JNK in the inflamed synovial membrane. Microphotographs showing synovial tissue of human 
tumour necrosis factor transgenic (hTNFtg) mice stained for the phosphorylated forms of p38 mitogen-activated protein kinase (MAPK)α  (upper 
panels) and extracellular signal-regulated kinase (ERK; middle panels), and cell-specific markers for (a,b) macrophages, (c,d) fibroblasts, (e,f) T lym-
phocytes and (g,h) B lymphocytes. p38MAPKα  is most frequently present in macrophages (panel a; simultaneous brown and blue staining, black 
arrows) and less frequently in fibroblasts (panel c; black arrows). Usually, T cells (panel e, white arrowhead) and B cells (panel g; white arrowhead) 
are negative for activated p38MAPKα  (black arrowheads). Activated ERK is present most frequently in macrophages (panel b) and fibroblasts (panel 
d; simultaneous brown and blue staining, black arrows), whereas it (black arrowheads) is only rarely expressed in T cells (panel g) and B cells (panel 
h; white arrowheads). Original magnification 1000×. In the lower panels, bars indicate the relative number of cells exhibiting activation of (i) 
p38MAPKα , (j) ERK and (k) JNK. Analyses were performed for T lymphocytes, B lymphocytes, synovial fibroblasts and macrophages. Activation of 
p38MAPKα  was significantly more frequent in macrophages than in T cells, B cells and fibroblasts (all P < 0.05); activation of ERK was significantly 
more abundant in macrophages and fibroblasts than in T cells and B cells (P < 0.05). Data are expressed as mean ± standard error of the mean.Arthritis Research & Therapy    Vol 7 No 5    Görtz et al.
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therapeutics may become feasible extensions of TNF block-
ade. Because TNF is currently considered a major target of
antirheumatic drugs, studies of its role in activating signalling
pathways in the synovial membrane deserve further attention.
Such studies may be conducted using an in vivo disease
model based on overexpression of TNF [7]. Although this
model has limitations as a model for RA, as is evident from its
independence from an autoimmune pathogenesis of arthritis,
it nonetheless allows study of synovial changes provoked by a
single, well defined trigger, namely TNF.
The data obtained in the present study reveal that induction of
synovitis by TNF is accompanied by activation of p38MAPKα
and ERK signalling in synovial macrophages and fibroblasts in
vivo. Earlier in vitro studies showed that TNF-mediated cellular
effects, including induction of cytokines such as IL-6 and IL-8,
as well as the expression of matrix metalloproteinases such as
matrix metalloproteinase-13, are dependent on the activation
of p38MAPKα  and ERK [23,24]. Moreover, p38MAPKα  and
ERK can both transactivate nuclear factor-κ B – a transcription
factor known to be essential for inflammation [25]. Taken
together, our results support an important role for signalling
through p38MAPKα  and ERK in mediating the effects of TNF
in inflammatory joint disease. Macrophages and synovial
fibroblasts appear to be the major targets of TNF-induced
MAPK activation, whereas this process is of minor importance
in lymphocytes. This cellular pattern of MAPK activation is sim-
ilar to that observed in human RA, in which p38MAPKα  and
ERK are mainly activated in macrophages and fibroblasts but
not lymphocytes [18].
The observation that TNF leads to activation of p38MAPKα
and ERK in the synovial membrane indicates a potential role
for pharmacological inhibition of these two MAPKs in blocking
the deleterious effects of TNF on the joint. In fact, studies con-
ducted in animal models of arthritis have shown efficacy of
small molecule based inhibitors of p38MAPKα  in reducing
joint inflammation [14,15]. Inhibition of ERK activation has thus
far not been applied in inflammatory joint disease but it was
used in an experimental model of osteoarthritis [26]. In con-
trast to the aforementioned kinases, only limited activation of
JNK occurs upon stimulation by TNF. Considering the fact that
JNK is activated in the synovial membrane of RA [18], this may
point to a distinct regulation pattern for JNK in which TNF is
not the major player. Recent studies have revealed that JNK
activation in synovial cells depends on MEKK-2, an upstream
MAPK that is utilized by various growth and differentiation fac-
tors such as epidermal growth factor and c-kit [27-30]. This
suggests that other proinflammatory mechanisms, which act
independently from TNF, may lead to activation of JNK in the
synovium. The observation that blockade of JNK reduces
structural damage in collagen-induced arthritis – an autoim-
mune-triggered model of RA that does not exclusively depend
on TNF – supports this idea [31,32]. Apparently, such TNF-
independent mechanisms are also responsible for the expres-
Figure 4
Effects of cytokine blockade on MAPK activation in the inflamed syno- vial membrane Effects of cytokine blockade on MAPK activation in the inflamed syno-
vial membrane. Bars indicate the percentages of cells expressing the 
activated forms of (a) p38 mitogen-activated protein kinase (MAPK)α , 
(b) extracellular signal-regulated kinase (ERK) and (c) c-Jun amino-ter-
minal kinase (JNK) after treatment with vehicle (phosphate-buffered 
saline [PBS]), anti-tumour necrosis factor (aTNF), osteoprotegerin 
(OPG) and IL-1 receptor antagonist (IL-1ra). Anti-TNF significantly 
reduced expression of activated p38MAPKα  and ERK; IL-1ra only 
affected p38MAPKα  activation; and OPG led to changed MAPK acti-
vation in the synovial membrane. Data are expressed as mean ± stand-
ard error of the mean. *P < 0.05.Available online http://arthritis-research.com/content/7/5/R1140
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sion of the δ -isoform of p38MAPK in the synovial fibroblast,
which is activated by retrotransposable viral sequences
termed L1 elements [33].
Currently used cytokine blockers interfere with the binding of
the target cytokine with its receptor. As a consequence, the
intracellular signalling pathways of the respective cytokine that
undergo activation should be blocked or at least inhibited
upon use of the cytokine blocker. However, this concept has
been poorly investigated. Part of the present study addressed
the role of cytokine blockers on TNF-induced MAPK activation.
Blockade of TNF significantly reduced activation of both
p38MAPKα  and ERK in the synovial membrane, indicating that
the intracellular effects of TNF can be inhibited. This suggests
that anti-TNF therapy reduces key signalling pathways in the
synovial membrane, such as the MAPKs, and thereby reduces
inflammatory response in the tissue exposed to TNF. Reduc-
tion in MAPK activation on cytokine blockade was effective
throughout the different cellular compartments and did not sig-
nificantly change the distrubution of MAPK activation among
the various cell types. However, we were unable to reverse
MAPK activation with TNF blockade to the level in wild-type
mice, suggesting that upregulation of inflammatory mediators
downstream of TNF plays a role in synovial MAPK activation.
Indeed, inhibition of IL-1 also reduced p38MAPKα  activity but
not ERK activation, suggesting that at least part of TNF-medi-
ated effects on p38MAPKα  are mediated through IL-1. This
contributes to the current hypothesis that IL-1 is an important
downstream mediator of TNF. It is also in accordance with the
observation that p38MAPKα  is essential for the proinflamma-
tory action of IL-1 [34]. In contrast, blockade of RANK ligand
by osteoprotegerin did not change synovial MAPK activation,
which is in good agreement with the observation that blockade
of RANK ligand lacks efficacy on synovial inflammation but
specifically targets bone degradation in arthritis [19,35,36].
Conclusion
We show here that TNF leads to activation of two of three
MAPK families, p38MAPKα  and ERK in the synovial mem-
brane  in vivo. Inference with the activation of these two
MAPKs may therefore be an interesting goal for current and
future drug development aimed at inhibiting synovial
inflammation.
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